Bioelectronic Medicine NON - INVASIVELY TARGETING IMMUNE SYSTEM RESPONSES 2021 DECEMBER INVESTOR PRESENTATION 2 This presentation contains forward - looking statements . All statements other than statements of historical

1 Bioelectronic Medicine NON -

INVASIVELY TARGETING IMMUNE SYSTEM RESPONSES 2021 DECEMBER INVESTOR PRESENTATION

2 This presentation contains forward

- looking statements . All statements other than statements of historical facts contained in this presentation may be forward - looking

statements . Statements regarding our future results of operations and financial position, economic performance, business strategy and

plans and objectives of management for future operations, including, among others, statements regarding our expected growth, acquisition

strategies, investments, and future capital expenditures are all forward looking statements . Without limiting the generality of the

foregoing, words such as "may," "will," "should," "expect," "believe," "anticipate,"

"intend," "could," "estimate," "target," "project," "might,"

"plan," "predict" or "continue" or the negative or other variations thereof or comparable terminology

are intended to identify forward - looking statements . We caution you that any such forward - looking statements are not guarantees

of future performance, and are subject to risks, assumptions and uncertainties that are difficult to predict and beyond our ability and

control . Although we believe that the expectations reflected in these forward - looking statements are reasonable as of the date made,

actual results may prove to be materially different from the results expressed or implied by the forward - looking statements . Any differences

could be caused by a number of factors, including but not limited to : our anticipated needs for working capital ; our ability to secure

additional financing ; regulatory or legal developments in the United States and other countries ; our expectation regarding timing,

costs, conduct and development of our product candidates ; and our efforts to expand our products and business . Many of the important

factors that will determine these results are beyond our ability to control or predict . Accordingly, you should not place undue reliance

on any such forward - looking statements . Any forward - looking statement speaks only as of the date on which it is made, and, except

as otherwise required by law, we do not undertake any obligation to publicly update or review any forward - looking statement, whether

as a result of new information, future developments or otherwise . New factors emerge from time to time, and it is not possible for us

to predict which will arise . We cannot assess the impact of each factor on our business or the extent to which any factor, or combination

of factors, may cause actual results to differ materially from those contained in any forward - looking statements . In addition, statements

that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject . These statements are

based upon information available to us as of the date made, and while we believe such information forms a reasonable basis for such statements,

such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive

inquiry into, or review of, all potentially available relevant information . These statements are inherently uncertain, and you are cautioned

not to place undue reliance upon these statements . Unless otherwise indicated, information contained in this presentation concerning

our industry, competitive position and the markets in which we operate is based on information from independent industry and research

organizations, other third - party sources, as well as data from our internal research, and are based on assumptions made by us upon

reviewing such data, and our experience in, and knowledge of, such industry and markets, which we believe to be reasonable . In addition,

projections, assumptions and estimates of the future performance of the industry in which we operate, and our future performance are

necessarily subject to uncertainty and risk due to a variety of factors, which could cause results to differ materially from those expressed

in the estimates made by the independent parties and by us . This presentation shall not constitute an offer to sell or the solicitation

of an offer to buy our securities . FORWARD LOOKING STATEMENTS

3 Management Introductions LEADERSHIP

TEAM Jennifer Ernst Chief Executive Officer, Co - founder, MBA Built Tivic Health from founding to IPO in 5 years. Took prior company

(Thin Film Electronics) from 8 - person R&D team to $480MM market cap in < 5 years, as CEO of US subsidiary. Blake Gurfein Chief

Scientific Officer, Ph.D. Neuroscientist, Asst. Prof. of Medicine, UCSF. Pfizer, EMD Serono. Named to 40 under 40, Silicon Valley Business

Journal. Four prior neuromodulation products. Briana Benz Chief Financial Officer, MBA 30 years broad based financial, investment banking

and high - growth company leadership. Built over $800M in market value. Led multiple acquisition and integration activities. Previously,

investment banker with Merrill Lynch Capital Markets. CPA. MBA, Columbia Business School. Ryan Sabia VP, Sales & Operations BS, Finance

Global sales, marketing, and operations for omnichannel and ecommerce growth companies. Background in both health and consumer products.

Dean Zikria Global Strategy, J&J, Pfizer, Allergy/Asthma Chief Commercial Officer, Intuity Medical. Commercial leadership Pfizer,

J&J. Healthcare Strategy at Accenture, Deloitte. Growth leadership in Asthma & Allergy. MBA, Rutgers. BS, Biology, Rutgers. Karen

Drexler Public Board Member, Compensation Chair, Nominating & Governance Chair Board of ResMed (NYSE: RSMD), OutSet Medical (NASDAQ:

OM) and VIDA Diagnostics. Sale of companies to Roche, J&J. MBA, Stanford; BSE Princeton University. Sheryle Bolton Hult Faculty,

Board Chair, Audit Committee Chair Experienced public company CEO. International Board Member and serial entrepreneur. Prior leadership

of successful neuroscience IPO. Merrill Lynch Capital Markets. MBA, Harvard Business School. BOARD OF DIRECTORS 2021 Female Founders

100 2021 Top 25 Women in Consumer Healthtech.

4 Investment Highlights TIVIC HEALTH:

FOUNDED 2016 23,000 Units Sold 2 FDA Clearances & CE Mark Over 2 3 4 18 500 + PEER - REVIEWED PUBLICATIONS REGULATORY CLEARANCES

ISSUED PATENTS PATENTS PENDING 4 - AND 5 - STAR REVIEWS Commercial - phase in high - growth bioelectronics sector. FDA & CE cleared,

award - winning product for sinus pain and congestion. $8B available US market , estimated based on company's proprietary research.

Selling on Tier 1 retailers , incl. Amazon, BestBuy, Walmart, Walgreens, and others. Second generation architecture in development, optimized

for low - cost manufacturing. Potential applications in migraine and other indications. Experienced management , with public company

growth experience. Revenue Growth (9 - month YOY) 64 %

5 THE BIG IDEA The body is an electro

chemical system. Electrons can be used as medicine. 5 Bioelectronic medicine "represents a multibillion dollar opportunity,

[and has the] potential to become a pillar of medical treatment."

6 Electrons as medicine BIOELECTRONICS'

ORIGINS 1960s Pacemakers 2010s Sleep Apnea, Rheumatoid Arthritis 1990s Deep Brain, Spinal Cord 2020s Non - Invasive Bioelectronics

Bioelectronic medicine treats disease by tuning electrical signaling carried along neural (nerve) pathways. Tivic Health focuses

on tuning these signals non - invasively. Non - invasive = Shorter development time, lower risk, broader applicability. INVASIVE

7 Clears congestion, stops sinus

pain, non - invasively. ClearUP User glides tip along facial skin around cheek, nose, brow (sinus regions) for 5 minutes,

twice daily and as needed. Low - level pulsed current flows from tip, through sinus passages. Launched late 2019. Available

through Tier 1 online retailers. $149 list price. Margins both volume and channel dependent. FIRST COMMERCIAL PRODUCT Featured

on and more " Changed my life! "Unbelievable" "Godsend" "Amazing!" As of 10.21.2021

8 OUR PLATFORM FOR Non - invasive

Peripheral Nerve Stimulation Programmable Parameters produce varied biological responses for different diseases and conditions Patented

Form Factor enables low - level electrical current to penetrate deeply through tissue Proprietary Algorithms detect optimal treatment

zones, personalize therapeutic stimulation

9 PIPELINE Other Potential Use

Cases Postoperative Pain following sinus surgery 600,000 FESS (sinus) surgeries annually in US, alternative to opioids Temporomandibular

Joint Disorder (TMJ) Tinnitus Trigeminal Neuralgia Otitis Media / Ear Infection Migraine Headache 39M people in US, 1B people w orldwide

Extensible technology Additional potential market opportunities associated with stimulation of nerves of the face and head (trigeminal,

vagus, facial). PRODUCT / PRODUCT LINE THERAPEUTIC AREA DISCOVERY /R&D CLINICAL FEASIBILITY PIVOTAL STUDY REGULATORY CLEARANCE COMMERCIAL

DISTRIBUTION CONTENT PARTNERS ClearUP Sinus Pain and Congestion npdPP Post - Operative Pain npdMI Migraine Sinus Pain and Congestion

(commercial) Estimated 200M US adults, $8B estimated US market, global opportunity

10 K182025 CE 704687 DEN200006

ISSUED PATENTS (issued in 2020 & 2021) 5 PATENTS PENDING 18 STRONG INTELLECTUAL PROPERTY THREE REGULATORY CLEARANCES PEER - REVIEWED

PUBLICATIONS Open - label study. Continuous reduction in pain and congestion over 4 - weeks of at - home use. Published: Bioelectronic

Medicine Double - blind, sham - controlled, randomized trial. Reductions in pain and congestion vs. sham 10 minutes after treatment.

Published: International Forum of Allergy & Rhinology ROBUST FOUNDATIONS

11 Oral & Intranasal Decongestants

Antihistamines Treat itchiness Not effective for congestion and pain Headache, sleepiness, fatigue, dry mouth,

and sore throat Insomnia, nervousness, heart palpitations, headache, sweating, nausea, trembling, weakness, rebound Saline Irrigation

Messy / impractical Not portable $706M US market Drugs Dominate Sinus Care but 90% of sufferers interested

in treatments that decrease use of drugs 1 (1) Market research study of 600 people with recurring sinus conditions. Company sponsored

research conducted by Research America . COMPETITIVE LANDSCAPE Intranasal Steroids Powerful drug Burning, stinging, nose

bleeds, headache, nausea, vomiting, diarrhea, sore throat, dizziness, cough

12 82% preferred ClearUP to current

treatments 1 STRONG CONSUMER PREFERENCE No pills, no sprays, nothing in the nose No drugs, no significant side effects

reported 2 Use any time, anywhere, whenever and as often as needed (2) Most common side effect: 0.02% reported mild skin irritation

in clinical studies and post - market surveillance. (1) Data from a 71 - person double - blind, randomized, controlled clinical study

conducted by Stanford Medicine.

13 Maul XA, Borchard NA, Hwang

PH, Nayak JV. Microcurrent technology for rapid relief of sinus pain: a randomized, placebo-controll ed, double-blinded clinical trial.

Int Forum Allergy Rhinol. 2019;9:352 - 356. Fast - acting Double - blind, randomized, sham - controlled trial examined acute response.